Patent benefit sharing at CNIO: key insights for researchers in 2026

Key data

Research and technical staff at the National Center for Oncological Research (CNIO) now have clear rules about how much they are entitled to when a discovery generates commercial income. The Order CNU/791/2026, of July 24, published in the BOE on July 31, 2026, develops the framework of the Law 14/2011 on Science, Technology and Innovation and Royal Decree 55/2002, and establishes the criteria for calculating and distributing the benefit from the exploitation of research results at the CNIO Foundation (F.S.P.).

Until now, the absence of specific rules generated uncertainty for both researchers and the institution itself. This order closes that regulatory gap with concrete and binding criteria.

What does this regulation establish?

The order regulates five fundamental aspects of the process of exploiting research results at CNIO:

• Key definitions: The concepts that define what is understood as a research result capable of generating economic rights are established.
• Results that generate rights: Not all R&D results generate economic participation. The regulation clarifies which ones do.
• Calculation of exploitation benefit: Criteria are set to determine which income and costs are computed to obtain the net distributable benefit.
• Accrual periods: The moment when the right to receive economic participation arises is regulated.
• Distribution in thirds: The distribution follows the formula of three equal parts, as detailed in the following table.

The regulation explicitly clarifies that this participation does not have the status of salary or remuneration, which has direct implications for contributions and the researcher's tax status.

Additionally, the Foundation is required to implement an analytical accounting system by projects, an essential tool for correctly calculating the exploitation benefit of each result.

Economic and operational impact

The budget impact declared in the regulation is null and does not generate additional administrative burdens for third parties. However, at the internal level of CNIO, the order does imply relevant operational changes:

• Implementation of analytical accounting by projects: The Foundation must develop or adapt its accounting system to track income and costs by research project, so that the exploitation benefit can be calculated individually.
• Legal clarity for researchers: Since it does not count as salary, participation in benefits does not affect the contribution base or salary supplements linked to ordinary remuneration. This may have tax implications that each researcher should assess with their advisor.
• Institutional legal certainty: CNIO now has a clear framework for negotiating licenses and exploitation contracts, knowing in advance how the generated income will be distributed.

Who does it affect?

• Research staff of the CNIO Foundation (F.S.P.) participating in R&D+i projects with results susceptible to commercial exploitation.
• Technical staff at CNIO linked to research projects that generate protectable results (patents, utility models, trade secrets, software, etc.).
• The CNIO Board of Trustees, which must establish the distribution criteria for the third third.
• The economic and financial management area of CNIO, responsible for implementing analytical accounting by projects.
• Companies or entities that license or exploit CNIO results, as the internal distribution framework may influence negotiation conditions.

Practical example

Suppose CNIO licenses an oncology patent to a pharmaceutical company and obtains a net exploitation benefit of 300,000 euros in one fiscal year, after deducting the computable costs according to the order's criteria.

The distribution would be as follows:

The 100,000 euros corresponding to the authors would be distributed among the researchers listed as creators of the result, according to the criteria that the order itself and CNIO establish internally. This amount would not be considered salary, so it would not contribute to Social Security as ordinary remuneration, although it would be taxable in the researcher's personal income tax.

What should companies do now?

1. Review contracts with CNIO researchers: If your company collaborates with CNIO or licenses results, verify how this new distribution framework affects the agreed conditions.
2. Implement analytical accounting by projects: The CNIO Foundation must begin as soon as possible the design or adaptation of its accounting system to comply with this obligation.
3. The Board of Trustees must approve the criteria for the third third: Without these approved criteria, the distribution of the third portion remains pending. It is a priority and urgent action.
4. Inform research and technical staff: Those affected must know their economic rights, the non-salary nature of participation, and the tax implications for their personal income tax.
5. Consult with tax advisors: Although participation is not salary, it is taxable. Researchers who will receive these amounts should plan their tax return in advance.

Official source

Consult complete regulation in official source

Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-16664